Oramed Pharmaceuticals
ORMP
75 hedge funds and large institutions have $51.5M invested in Oramed Pharmaceuticals in 2021 Q2 according to their latest regulatory filings, with 39 funds opening new positions, 17 increasing their positions, 8 reducing their positions, and 8 closing their positions.
388% more first-time investments, than exits
New positions opened: 39 | Existing positions closed: 8
310% more capital invested
Capital invested by funds: $12.6M → $51.5M (+$39M)
113% more repeat investments, than reductions
Existing positions increased: 17 | Existing positions reduced: 8
70% more funds holding
Funds holding: 44 → 75 (+31)
66% more call options, than puts
Call options by funds: $4.82M | Put options by funds: $2.91M
8.06% more ownership
Funds ownership: 4.21% → 12.27% (+8.1%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$13.6M |
| 2 |
State Street
Boston,
Massachusetts
|
+$4.03M |
| 3 |
Northern Trust
Chicago,
Illinois
|
+$2.41M |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$2.3M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.43M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SPIA
Steward Partners Investment Advisory
New York
|
-$686K |
| 2 |
JSMC
Jess S. Morgan & Co
Los Angeles,
California
|
-$660K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$644K |
| 4 |
ECM
ExodusPoint Capital Management
New York
|
-$533K |
| 5 |
Ameriprise
Minneapolis,
Minnesota
|
-$122K |
ORMP Hedge Fund Activity: Q2 2021 in Review
75 of the 5,767 institutional investors tracked by Wall St. Rank reported a position in Oramed Pharmaceuticals (ORMP) for Q2 2021, worth a combined $51.5M — up 310% from $12.6M a quarter earlier.
Buyers outnumbered sellers: 39 funds opened new ORMP positions and 8 closed out — a net gain of 31 holders — while 17 added to existing stakes and 8 trimmed.
The largest buyer was BlackRock, adding an estimated $13.6M. The largest seller was Steward Partners Investment Advisory, cutting an estimated $686K.
- 75 institutional investors held Oramed Pharmaceuticals (ORMP) as of Q2 2021, up from 44 in Q1 2021.
- Funds reported $51.5M of Oramed Pharmaceuticals stock for Q2 2021, up 310% quarter-over-quarter.
- 39 funds opened new Oramed Pharmaceuticals positions in Q2 2021 and 8 closed out, a net change of +31 holders.
- The largest Oramed Pharmaceuticals buyer in Q2 2021 was BlackRock, an estimated $13.6M added.
- The largest Oramed Pharmaceuticals seller in Q2 2021 was Steward Partners Investment Advisory, an estimated $686K sold.
Based on aggregated 13F filings for Q2 2021.